Pay in 4 interest-free payments of $6.96 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Published Phase 2 data shows: Dose Group Discontinuation Due to AE Placebo 0% 1 mg 2.9% 4 mg (escalated) 5.7% 8 mg (escalated) 5.0% 12 mg (escalated) 8.3% For context, discontinuation rates in semaglutide 2.4 mg trials (STEP program) were approximately 7%, and tirzepatide 15 mg trials (SURMOUNT) reported approximately 6-7%
This experiment took place over 56 weeks and was considered a phase 3a, open-label, parallel-group, randomized controlled trial that included 813 participants diagnosed with type 2 diabetes being actively treated with oral antidiabetic drugs
The effectiveness of a new topical formulation containing GSH-C4 and hyaluronic acid in seborrheic dermatitis: preliminary results of an exploratory pilot study
Fournial, A., & Mondon, P
US$ 21.48
US$ 29.16
US$ 25.38
US$ 25.56
US$ 28.90
US$ 19.99
